跳至主要内容
临床试验/NCT01688050
NCT01688050已完成不适用

TRANSFIX - Zenith® TX2® Low Profile Endovascular Graft for Blunt Thoracic Aortic Injury

Cook Research Incorporated42 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年1月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
42
主要终点
All-cause Mortality

研究概览

简要总结

The TRANSFIX study is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® TX2® Low Profile Endovascular Graft for treatment of Blunt Thoracic Aortic Injury.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Vessels suitable for endovascular access and stent graft placement
  • Blunt thoracic aortic injury of the descending thoracic aorta
  • At least 16 years of age
  • Informed consent given by patient or legally authorized representative

排除标准

  • Clinical considerations that would compromise patient safety or study outcomes
  • Unsuitable arterial anatomy

结局指标

主要结局

All-cause Mortality

时间窗: 30 days

Aortic Injury-related Mortality

时间窗: 30 days

Any death determined by the independent clinical events committee to be causally related to the initial implant procedure, secondary intervention, or rupture of the transected aorta.

Device Success

时间窗: 30 days

Technical success (successful access, deployment, and patency of the Zenith® TX2® Low Profile Endovascular Graft), and freedom from the following: device collapse, type I or type III endoleaks requiring reintervention, and conversion to open surgical repair.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (42)

Loading locations...

相似试验